About Bonum Therapeutics
Bonum Therapeutics is a company based in Seattle (United States) founded in 2016 was acquired by Roche in September 2022. It operates as a HealthTech. Bonum Therapeutics has raised $37.15 million across 3 funding rounds from investors including Roche, RiverVest Venture Partners and Digitalis Ventures. The company has 23 employees as of December 31, 2021. Bonum Therapeutics offers products and services including Antibody-Controlled Cytokine Therapeutics and Regulated Protein Therapeutics. Bonum Therapeutics operates in a competitive market with competitors including TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others.
- Headquarter Seattle, United States
- Employees 23 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Bonum Therapeutics
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Bonum Therapeutics
Bonum Therapeutics offers a comprehensive portfolio of products and services, including Antibody-Controlled Cytokine Therapeutics and Regulated Protein Therapeutics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapeutics are developed to enhance anti-tumor immune response.
Proteins are engineered for targeted and regulated biological activity.
Unlock access to complete
Funding Insights of Bonum Therapeutics
Bonum Therapeutics has successfully raised a total of $37.15M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $8.81 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $8.8M
-
First Round
First Round
(01 Nov 2018)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2021 | Amount | Series B - Bonum Therapeutics | Valuation | Roche , RiverVest Venture Partners |
|
| May, 2020 | Amount | Series A - Bonum Therapeutics | Valuation |
investors |
|
| Nov, 2018 | Amount | Series A - Bonum Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Bonum Therapeutics
Bonum Therapeutics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, RiverVest Venture Partners and Digitalis Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Digitalis Ventures is engaged in health-focused investments.
|
Founded Year | Domain | Location | |
|
Private investments are managed for institutional investors globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Bonum Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Bonum Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Bonum Therapeutics Comparisons
Competitors of Bonum Therapeutics
Bonum Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer are developed by targeting ecDNA.
|
|
| domain | founded_year | HQ Location |
T-cell therapies for cancer treatment are developed by Bolt Biotherapeutics.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Bonum Therapeutics
Frequently Asked Questions about Bonum Therapeutics
When was Bonum Therapeutics founded?
Bonum Therapeutics was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Where is Bonum Therapeutics located?
Bonum Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Bonum Therapeutics a funded company?
Bonum Therapeutics is a funded company, having raised a total of $37.15M across 3 funding rounds to date. The company's 1st funding round was a Series A of $6M, raised on Nov 01, 2018.
How many employees does Bonum Therapeutics have?
As of Dec 31, 2021, the latest employee count at Bonum Therapeutics is 23.
What does Bonum Therapeutics do?
Bonum Therapeutics is engaged in the development of innovative antibody-controlled therapeutics designed for targeted and regulated activity. The companys platform creates highly active and less toxic medicines, with a primary focus on cancer treatment through cytokine-based therapies that enhance anti-tumor immune responses. Additional applications are explored in autoimmune diseases, metabolic disorders, and pain management. Programs target immune cells and other cell types within the tumor microenvironment, utilizing dual binding antibodies that remain inactive until bound to their specific targets. The reversible regulation mechanism ensures safety by deactivating the therapeutic if it disengages from the target.
Who are the top competitors of Bonum Therapeutics?
Bonum Therapeutics's top competitors include Lyell Immunopharma, GigaGen and Shattuck Labs.
What products or services does Bonum Therapeutics offer?
Bonum Therapeutics offers Antibody-Controlled Cytokine Therapeutics and Regulated Protein Therapeutics.
Who are Bonum Therapeutics's investors?
Bonum Therapeutics has 5 investors. Key investors include Roche, RiverVest Venture Partners, Digitalis Ventures, American Century Private Investments, and Codon Capital.